Infant Mortality Reduction by the Mass Administration of Azithromycin

• Status: Not yet recruiting
• Trial end date: 2025-01-30
• Target enrollment: 0
• Participant gender: All

Summary

This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: Bill and Melinda Gates Foundation; Centre de Recherche en Sante de Nouna, Burkina Faso; Helen Keller International
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

Community eligibility criteria:

• Located in one of the three selected regions: SudOuest, Centre-Ouest, Hauts-Bassins

• Verbal consent of the community leader is obtained

Inclusion criteria for children:

• Aged 1 to 11 months

• Living in one of the communities participating in the study

Exclusion Criteria:

Community exclusion criteria:

• Inaccessible or unsafe for the study team

Exclusion criteria for children:

• Known allergy to macrolides